The results showed a TRIM28 dosage-dependent change of several genes, which were demonstrated to be involved in the cell cycle progression, especially in BCR-ABL CML (e.g., CDKN1A (p21) and CCND2 (Cyclin D2)), which all responded to the G1/S phase progression (Figure 4a). This evidence concerns the gene TRIM28 and chronic myelogenous leukemia, BCR-ABL1 positive.